Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Biomarkers of DONQ52 in Celiac Disease Patients (LILY Study)
NCT05425446 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Biomarkers of DONQ52 in Celiac Disease Patients (LILY Study)
- Lead sponsor
- Chugai Pharmaceutical
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 19, 2022
- Completion date
- January 17, 2025
- Enrollment
- 56 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.